Sarcomatrix
Sarcomatrix is a biopharmaceutical company dedicated to developing innovative therapies for muscle-wasting diseases, including muscular dystrophies and related conditions. The company focuses on scientific innovation, patient-centric solutions, and advancing a pipeline of small molecule drugs and protein replacement therapies. Their mission is to address unmet medical needs and improve lives through groundbreaking treatments.
Industries
Nr. of Employees
small (1-50)
Sarcomatrix
San Francisco, California, United States, North America
Products
Oral small-molecule Hippo‑YAP pathway modulator (lead integrin activator)
An orally administered small-molecule candidate designed to upregulate muscle-specific integrin expression via Hippo‑YAP pathway modulation to promote muscle regeneration; being advanced through preclinical and IND-enabling studies.
Recombinant laminin-111 protein replacement candidate
A recombinant laminin-111 protein intended as replacement therapy to restore extracellular matrix support for patients with LAMA2-related muscular dystrophy and potentially other muscle disorders.
S-969
A novel oral, once-daily small molecule that upregulates the muscle-specific alpha-7 beta-1 integrin (ITGA7) to support muscle fiber rebuilding and myogenesis.
lead oral small molecule therapy
Sarcomatrix's lead oral small molecule therapy is aimed at treating muscle-wasting diseases such as Duchenne muscular dystrophy (DMD), sarcopenia, and cachexia by targeting underlying mechanisms of muscle degeneration to preserve and restore muscle function across diverse patient populations.
Protein replacement therapy using laminin-111
A potential treatment for LAMA2-related muscular dystrophy, Duchenne muscular dystrophy, and other muscular dystrophies, promoting muscle repair and regeneration.
recombinant human laminin-111 (rhLAM-111)
A potential therapy for LAMA2-related muscular dystrophy (LAMA2-RD) and Duchenne Muscular Dystrophy (DMD), showing promise in preclinical studies to support muscle integrity and function.
Oral small-molecule Hippo‑YAP pathway modulator (lead integrin activator)
An orally administered small-molecule candidate designed to upregulate muscle-specific integrin expression via Hippo‑YAP pathway modulation to promote muscle regeneration; being advanced through preclinical and IND-enabling studies.
Recombinant laminin-111 protein replacement candidate
A recombinant laminin-111 protein intended as replacement therapy to restore extracellular matrix support for patients with LAMA2-related muscular dystrophy and potentially other muscle disorders.
S-969
A novel oral, once-daily small molecule that upregulates the muscle-specific alpha-7 beta-1 integrin (ITGA7) to support muscle fiber rebuilding and myogenesis.
lead oral small molecule therapy
Sarcomatrix's lead oral small molecule therapy is aimed at treating muscle-wasting diseases such as Duchenne muscular dystrophy (DMD), sarcopenia, and cachexia by targeting underlying mechanisms of muscle degeneration to preserve and restore muscle function across diverse patient populations.
Protein replacement therapy using laminin-111
A potential treatment for LAMA2-related muscular dystrophy, Duchenne muscular dystrophy, and other muscular dystrophies, promoting muscle repair and regeneration.
recombinant human laminin-111 (rhLAM-111)
A potential therapy for LAMA2-related muscular dystrophy (LAMA2-RD) and Duchenne Muscular Dystrophy (DMD), showing promise in preclinical studies to support muscle integrity and function.
Services
End-to-end preclinical program support including efficacy, PK/PD, toxicology, bioanalysis and coordination with CROs to generate data for IND submissions.
Implementation and integration of validated digital platforms for clinical trial planning, execution, quality management and regulatory compliance.
Collaborative discovery and translational research with university labs to support target validation, screening and mechanism-of-action studies.
End-to-end preclinical program support including efficacy, PK/PD, toxicology, bioanalysis and coordination with CROs to generate data for IND submissions.
Implementation and integration of validated digital platforms for clinical trial planning, execution, quality management and regulatory compliance.
Collaborative discovery and translational research with university labs to support target validation, screening and mechanism-of-action studies.
Expertise Areas
- Small-molecule drug discovery for muscle disease
- Protein replacement therapy development
- Preclinical development and IND-enabling studies
- Clinical trial design and endpoint selection
Key Technologies
- High-throughput small-molecule screening
- Hippo‑YAP pathway modulation
- Integrin activation assays
- Recombinant protein therapeutics (laminin-111)
News & Updates
Sarcomatrix has renewed its EU Orphan Drug Designation for rhLaminin-111 as a potential therapy for LAMA2-Related Dystrophies and is expanding research into Duchenne Muscular Dystrophy.
An interview with David Craig discussing the development of S-969, regulatory challenges, clinical trial design, manufacturing, IP protection, and strategic partnerships.
Sarcomatrix has partnered with Celito Tech to leverage their Helyx Platform for streamlining clinical trial planning, execution, and regulatory management.
Sarcomatrix Therapeutics Launches Regulation D Offering to Advance Novel Oral Muscle Disease Therapy
Sarcomatrix is raising funds to support IND preparation and first-in-human studies for its lead therapy, targeting muscle-wasting diseases.
Recognition for progress in advancing treatments for muscle diseases like sarcopenia and muscular dystrophy.
Sarcomatrix has renewed its EU Orphan Drug Designation for rhLaminin-111 as a potential therapy for LAMA2-Related Dystrophies and is expanding research into Duchenne Muscular Dystrophy.
An interview with David Craig discussing the development of S-969, regulatory challenges, clinical trial design, manufacturing, IP protection, and strategic partnerships.
Sarcomatrix has partnered with Celito Tech to leverage their Helyx Platform for streamlining clinical trial planning, execution, and regulatory management.
Sarcomatrix Therapeutics Launches Regulation D Offering to Advance Novel Oral Muscle Disease Therapy
Sarcomatrix is raising funds to support IND preparation and first-in-human studies for its lead therapy, targeting muscle-wasting diseases.
Recognition for progress in advancing treatments for muscle diseases like sarcopenia and muscular dystrophy.